AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Protein Mdm4

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

O15151

UPID:

MDM4_HUMAN

Alternative names:

Double minute 4 protein; Mdm2-like p53-binding protein; Protein Mdmx; p53-binding protein Mdm4

Alternative UPACC:

O15151; Q2M2Y2; Q32SL2; Q6GS18; Q8IV83

Background:

Protein Mdm4, also known as Double minute 4 protein, Mdm2-like p53-binding protein, and p53-binding protein Mdm4, plays a crucial role in cellular processes. It is instrumental in regulating TP53, a key tumor suppressor gene, by inhibiting its cell cycle arrest and apoptosis functions. Mdm4's interaction with MDM2 further influences TP53's stability and activity, showcasing its pivotal role in cell cycle regulation and apoptosis.

Therapeutic significance:

Given its involvement in Bone marrow failure syndrome 6, characterized by hematopoietic defects and increased cancer susceptibility, Mdm4 presents a significant target for therapeutic intervention. Understanding the role of Protein Mdm4 could open doors to potential therapeutic strategies, especially in conditions where TP53 regulation is compromised.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.